COMPASS THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
COMPASS THERAPEUTICS, INC. (CMPX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $5.07 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $5.18, a 43.49% increase year-over-year.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.61, a 97.27% increase year-over-year.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.83, a 53.32% decline year-over-year.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.92.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $3.63, a 129.75% increase from fiscal 2024.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.58, a 57.18% decline from fiscal 2023.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.69, a 60.43% increase from fiscal 2022.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $2.30, a 54.18% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.07 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $5.18 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $3.63 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $3.61 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $3.61 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $3.61 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $1.58 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $1.57 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $1.82 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $1.83 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $3.69 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $3.76 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $3.80 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $3.92 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $2.30 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $2.30 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $2.29 10-Q · filed 2022-08-01 | |||
| 2021-12-31 | $5.02 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |